Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Influenza B hemagglutinin (HA) is a class I viral fusion protein and the primary surface antigen of the Influenza B virus, essential for viral infectivity (UniProt P03460). It functions by binding to terminal sialic acids on host cell surface glycoproteins, triggering receptor-mediated endocytosis, and subsequently mediating the fusion of the viral envelope with the endosomal membrane at low pH.
The BK-FLU mRNA construct, also known as "BNT161", is a nucleoside-modified messenger RNA vaccine candidate that encodes the HA protein of selected Influenza B strains. Upon administration, host cells translate the mRNA into HA protein, which then stimulates the immune system to produce neutralizing antibodies and activate T-cell responses. This target is critical for seasonal influenza prevention, although its high rate of mutation in the globular head region necessitates frequent vaccine updates to maintain efficacy against circulating lineages such as Victoria and Yamagata. Biotech development focuses on both increasing the breadth of the immune response and improving the speed of vaccine production through mRNA platforms.
Induction of neutralizing antibodies that block viral attachment to sialic acid receptors and prevent pH-dependent membrane fusion.
5 more in the full profile.
Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza B virus hemagglutinin (HA) (HA).